Opinion|Videos|October 14, 2024
COSMOS-CRC-01: Clinicopathologic Correlation of ctDNA With RFS
Author(s)Yoshiaki Nakamura, MD, PhD
Yoshiaki Nakamura, MD, PhD, discusses how the COSMOS-CRC-01 study demonstrated statistically significant recurrence-free intervals across various postoperative and adjuvant chemotherapy time points, highlighting the prognostic value of serial, tissue-free ctDNA assays for real-time detection of MRD vs single postchemotherapy assessments.
Advertisement
Episodes in this series
1. Please summarize the statistically significant recurrence-free intervals across the postoperative, post-ACT, and paired pre- and post-ACT analyses in the COSMOS-CRC-01 study.
2. Please address the prognostic value of serial, tissue-free, epigenomic ctDNA assays in detecting MRD in real time vs a single postchemotherapy time point.
Advertisement
Related to this article
Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.
Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.
The FDA converted the accelerated approval of pembrolizumab in TMB-high solid tumors to traditional approval, redefining TMB-high as at least 13 mut/Mb.
Following an end-of-phase 2 meeting with the FDA, Rgenta plans to start a phase 3 trial of oral RGT-61159 in adenoid cystic carcinoma in the first quarter of 2027.
The FDA granted fast track designation to SBE303, Samsung Bioepis’ investigational Nectin-4–targeting ADC, for advanced urothelial cancer following enfortumab vedotin.
The antibody-drug conjugate sofetabart mipitecan showed efficacy and safety, leading to selection of a phase 3 dose for the FRAmework-01 trial.
FDA grants orphan drug designation to onvansertib for relapsed or refractory CMML, boosting development of the PLK1 inhibitor after early signals of activity.
Findings highlight the need for individualized monitoring after discharge, despite low rates of severe toxicities.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Alignment Reached on Phase 3 Design for RGT-61159 in ACC
2
Sofetabart Mipitecan Elicits Responses Across FRα Levels in Ovarian Cancer
3
FDA Grants Traditional Approval to Pembrolizumab in TMB-High Solid Tumors
4
FDA Grants Fast Track Status to SBE303 in Urothelial Cancer
5